Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-02-13
2000-05-09
Elliott, George C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435375, 536 231, A61K 3170, C07H 2104, C12N 506
Patent
active
060604581
ABSTRACT:
The present invention provides a single-stranded oligodeoxyribonucleotide, which (i) comprises from about 5 to 11 bases, at least one of which is a substituted or an unsubstituted O.sup.6 -benzylguanine, and (ii) inactivates human AGT. The present invention also provides a single-stranded oligodeoxyribonucleotide, which can inactivate a mutant human AGT, which either is not inactivated by O.sup.6 -benzylguanine or is less inactivated by O.sup.6 -benzylguanine than by said single-stranded oligodeoxyribonucleotide. A phosphate of the single-stranded oligodeoxyribonucleotide can be replaced by a methylphosphonate or a phosphorothioate. The present invention also provides a composition comprising such an oligodeoxyribonucleotide. In addition, the present invention provides a method of enhancing the effect of an antineoplastic alkylating agent, which alkylates the O.sup.6 position of guanine residues in DNA, in the chemotherapeutic treatment of cancer in a mammal, which method comprises the co-administration to the mammal of a cancer-treatment effective amount of an antineoplastic alkylating agent and a chemotherapeutic treatment-enhancing amount of a present inventive oligodeoxyribonucleotide or composition thereof.
REFERENCES:
patent: 4199574 (1980-04-01), Schaeffer
patent: 4495190 (1985-01-01), Hagberg et al.
patent: 4751221 (1988-06-01), Watanabe et al.
patent: 4801710 (1989-01-01), MacCoss et al.
patent: 4965270 (1990-10-01), Harnden et al.
patent: 5075445 (1991-12-01), Jarvest et al.
patent: 5091430 (1992-02-01), Moschel et al.
patent: 5352669 (1994-10-01), Moschel et al.
patent: 5358952 (1994-10-01), Moschel et al.
patent: 5364904 (1994-11-01), Farmer et al.
patent: 5525606 (1996-06-01), Moschel et al.
patent: 5691307 (1997-11-01), Moschel et al.
Gerwitz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA 93: 3161-3163, Apr. 1996.
Gura. Antisense has growing pains. Science 270: 575-577, Oct. 1995.
Rojanasakul. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug. Delivery Rev. 18: 115-131, 1996.
Stull et al. Antigene, ribozyme, and aptamer nucleic acid drugs: Progress and prospects. Pharm. Res. 12: 465-483, Apr. 1995.
American Chemical Society, Chemical Abstracts Service Registry Handbook, Number Section 1965-1971, 11267R, col. 3, Registry No. 30360-74-8 (1965-71).
Beaman et al., in Zorbach and Tipson, Synthetic Procedures in Nucleic Acid Chemistry, 1, 41-43 (John Wiley & Sons, New York, NY 1968).
Beecham Group, "Preparation of Guaninie Derivatives and Their Use in Antiviral Preparations," 28-Heterocyles, 103:123509a (1985).
Bisacchi et al., Preparation of [1.beta.-(1.alpha.,2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxymethyl)cyc lobutyl]-6H-purin-6-one, Chem. Abs., 115:159683q (1991).
Bisacchi et al., Synthesis and Antiviral Activity of Enantiomeric Forms of Cyclobutyl Nucleoside Analogues, J. Med. Chem., 34, 1415-1421 (1991).
Boon et al., J. Chem. Soc., 96-102 (1951).
Bowles et al., "Synthesis and Antitumor Activity 9-(Tetrahydro-2-furyl)purine Analogs of Biologically Important Deoxynucleosides," J. Med. Chem. 6, 471-480 (1963).
Brix et al., "Androgen-linked Alkylating Agents: Biological Activity in MethylInitrosourea-induced Rat Mammary Carcinoma," J. Cancer Res. Clinical Oncology, 116, 538-549 (1990).
Carbon et al., "Synthesis and Reactions of 5-Bromomethyl- and 5-Chloromethyluracil," J. Org. Chem., 25, 1731-1734 (1960).
Chae et al., J. Med. Chem., 37 (3), 342-347 (1994).
Chae et al., J. Med. Chem., 38 (2), 359-365 (1995).
Christian et al., "Promising New Agents Under Development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute," Seminars in Oncology, 24(2), 219-240 (1997).
Ciocco et al., "Specific Labeling of O.sup.6 -Alkylguanine-DNA Alkyltransferase by Reaction with O.sup.6 -(p-Hydroxy[.sup.3 H]Methylbenzyl)guanine," Cancer Research, 55, 4085-4091 (1995).
Crone et al., Cancer Res., 53, 4750-4753 (1993).
Crone et al., "Mutations in Human O.sup.6 -Alkylguanine-DNA Alkyltransferase Imparting Resistance to O.sup.6 -Benzylguanine," Cancer Research, 54, 6221-6227 (1994).
Crone et al., "Mutations in the Ada O.sup.6 -Alkylguanine-DNA Alkyltransferase Conferring Sensitivity to Inctivation by O.sup.6 Benzylguanine and 2,4-Diamino-6-Benzyloxy-5-Nitrosopyrimidine," Carcinogenisis, 16(8), 1687-1692 (1995).
Daves, Jr., et al., J. Am. Chem. Soc., 82, 2633-2640 (1960).
Delia et al., Heterocycles, 20, 1805-1809 (1983).
Dolan et al., "Effect of O.sup.6 -Alkylguanine Pretreatment on the Sensitivity of Human Colon Tumor Cells to the Cytotoxic Effects of Chloroethylating Agents," Cancer Research, 46, 4500-4505 (1986).
Dolan et al., "Depletion of O.sup.6 -Alkylguanine-DNA Alkyltransferase Activity in Mammalian Tissues and Human Tumor Xenografts in Nude Mice by Treatment with O.sup.6 -Methylguanine," Cancer Chemother. Pharmacol., 25, 103-108 (1989).
Dolan et al., Cancer Commun., 2, 371-377 (1990).
Dolan et al., Proc. Natl. Acad. Sci. U.S.A., 87, 5368-5372 (1990).
Dolan et al., Cancer Res., 51, 3367-3372 (1991).
Dolan et al., "Comparison of the Inactivation of Mammalian and Bacterial O.sup.6 -Alkylguanine-DNA Alkyltransferases by O.sup.6 -Benzylguanine and O.sup.6 -Methylguanine," Carcinogenesis, 12 (12), 2305-2309 (1991).
Dolan et al., Biochem. Pharmacol., 46, 285-290 (1993).
Dolan et al., Cancer Chem. Pharmacol., 32, 221-225 (1993).
Dolan et al., "Metabolism of O.sup.6 -Benzylguanine, an Inactivator of O.sup.6 -Alkylguanine-DNA Alkyltransferase," Cancer Research, 54, 5123-5130 (1994).
Dolan et al., "O.sup.6 -Benzylguanine and Its Role in Chemotherapy," Clinical Cancer Research, 3, 837-847 (1997).
Door et al. in Cancer Chemotherapy Handbook, 715-742 (Elsevier Science Publishing, New York, NY 1980).
Edara et al., "Resistance of the Human O.sup.6 -Alkylguanine-DNA Alkyltransferase Containing Arginine at Coden 160 to Inactivation by O.sup.6 -Benzylguanine," Cancer Research, 56, 5571-5575 (1996).
Elder et al., "Differential Inactivation of Mammalian and Escherichia coli O.sup.6 -alkylguanine-DNA alkyltransferase by O.sup.6 -Benzylguanine," Biochem., 298, 231-235 (1994).
Felker et al., Cancer Chem. Pharmacol., 32, 471-476 (1993).
Fischer et al. in Cancer Chemotherapy Handbook, 3rd ed., 4-9, 60-61, 164-165, 171 (Year Book Medical Publishers, Inc., Chicago, IL 1989).
Folkman et al., "A New One-Step Method for the Preparation of 3',5'-Bisphosphates of Acid-Labile Deoxynucleosides," Chem. Res. Toxicol., 3, 536-539 (1990).
Fondy et al., "Haloacetamido Analogues of 2-Amino-2-deoxy-D-glucose and 2-Amino-2-deoxy-D-galactose. Syntheses and Effects on the Friend Murine Erythroleukemia," J. Med. Chem., 21 (12), 1222-1225 (1978).
Ford et al., "A Simple Method for Predicting Hydration Energies of Organic Cations Derived from Protonation of Alkylation of Neutral Oxygen and Nitrogen Bases," J. Org. Chem., 48, (13), 2226-2233 (1983).
Friedman et al., J. Natl. Cancer Inst., 84, 1926-1931 (1992).
Frihart et al., "Allylic Rearrangement from O.sup.6 to C-8 in the Guanine Series," J. Am. Chem. Soc., 95 (21), 7174-7175 (1973).
Gerson et al., "Synergistic Efficacy of O.sup.6 -Benzylguanine and 1,3-Bis(2-Chloroethyl-Nitrosourea (BCNU) in a Human Colon Cancer Xenograft Completely Resistant to BCNU Alone," Biochem. Pharmacol., 45 (2), 483-491 (1993).
Gerson et al., "Drug Resistance Mediated by DNA Repair: The Paradigm of O.sup.6 -Alkylguanine DNA Alkyltransferase," Proceedings of The American association for Cancer Research, 35, 699-700 (1994).
Gerster et al., J. Am. Chem. Soc., 87, 3752-3759 (1965).
Goodtzova et al., "Activation of Human O.sup.6 -Alkylguanine-DNA Alkyltransferase by DNA," Biochemistry, 33(28), 8385-8390 (1994).
Goodtzova et al., "Repair of O.sup.6 -Benzylguanine by the Escherichia coli Ada and Ogt and the Human O.sup.6 -Alkylguanine-DNA Alkyltransferase," The Journal of Biological Chemistry, 272(13), 8332-8339 (1997.
Green et al., "Preparation of Purine Acyclonucleoside Intermediates," Chem. Abs., 115:28993t (1991).
Hagberg et al., "Guanine Derivatives," 33-Carbohydrates,
Dolan M. Eileen
Moschel Robert C.
Pauly Gary T.
Pegg Anthony E.
ARCH Development Corporation
Elliott George C.
Larson Thomas G
The Penn State Research Foundation
The United States of America as represented by the Department of
LandOfFree
Oligodeoxyribonucleotides comprising O.sup.6 -benzylguanine and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligodeoxyribonucleotides comprising O.sup.6 -benzylguanine and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligodeoxyribonucleotides comprising O.sup.6 -benzylguanine and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1065190